Related Experiment Video
Updated: Aug 22, 2025
Large Scale Non-targeted Metabolomic Profiling of Serum by Ultra Performance Liquid Chromatography-Mass Spectrometry UPLC-MS
Published on: March 14, 2013
Plasma Metabolomic and Lipidomic Profiling of Metabolic Dysfunction-Associated Fatty Liver Disease in Humans Using an
Xiangping Lin1,2, Xinyu Liu2, Mohamed N Triba1
1Sorbonne Paris Nord University, Chemistry Structures Properties of Biomaterials and Therapeutic Agents Laboratory (CSPBAT), Nanomédecine Biomarqueurs Détection Team (NBD), The National Center for Scientific Research (CNRS), UMR 7244, 74 Rue Marcel Cachin, CEDEX, 93017 Bobigny, France.
Metabolic dysfunction-associated fatty liver disease (MAFLD) involves altered amino acid and lipid metabolism. This study reveals key metabolic pathways linked to MAFLD pathogenesis, offering new diagnostic and therapeutic insights.
Area of Science:
- Metabolomics
- Systems Biology
- Liver Disease Research
Background:
- Metabolic dysfunction-associated fatty liver disease (MAFLD) pathogenesis remains poorly understood, hindering prognostic and therapeutic advancements.
- The precise alterations in metabolic pathways during hepatic steatosis, inflammation, and fibrosis in MAFLD are unclear.
Purpose of the Study:
- To elucidate the human plasma metabolome and lipidome in MAFLD using a multiplatform omics approach.
- To identify specific metabolic pathways and molecular signatures associated with MAFLD development and progression.
Main Methods:
- Utilized untargeted nuclear magnetic resonance (NMR) spectroscopy and high-resolution mass spectrometry (HRMS).
- Applied a computational multiblock omics framework and metabolome-wide association studies.
- Analyzed plasma samples from obese patients with and without biopsy-confirmed MAFLD (n=63 vs n=19).
Main Results:
- Identified 16 metabolic pathways significantly associated with MAFLD.
- Highlighted alterations in amino acid, bile acid, fatty acid, glycerophospholipid, arachidonic acid, and steroid metabolism.
- Observed significant changes in energy metabolism, including amino acid and lipid profiles, linked to liver dysfunction and mitochondrial issues.
Conclusions:
- MAFLD is fundamentally a metabolism-related disorder with distinct metabolic alterations.
- Findings provide novel perspectives for developing diagnostic biomarkers and therapeutic strategies for MAFLD.
- Metabolic pathway dysregulation is central to MAFLD pathogenesis, impacting liver function and systemic health.
